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Abstract
Almost all dental diseases are caused by biofilms that consist of multispecies communities.
DJK-5, which is a short D-enantiomeric, protease-resistant peptide with broad-spectrum
anti-biofilm activity, was tested for its effect on oral multispecies biofilms. Peptide DJK-5 at
10 μg/mL effectively prevented the growth of these microbes in culture media in a time-
dependent manner. In addition to the prevention of growth, peptide DJK-5 completely killed
both Streptococcus mutans and Enterococcus faecalis suspended from biofilms after 30
minutes of incubation in liquid culture media. DJK-5 also led to the effective killing of
microbes in plaque biofilm. The proportion of bacterial cells killed by 10 μg/mL of DJK-5 was
similar after 1 and 3 days, both exceeding 85%. DJK-5 was able to significantly prevent bio-
film formation over 3 days (P = 0.000). After 72 hours of exposure, DJK-5 significantly
reduced and almost completely prevented plaque biofilm production by more than 90% of
biovolume compared to untreated controls (P = 0.000). The proportion of dead biofilm bacte-
ria at the 10 μg/mL DJK-5 concentration was similar for 1- and 3-day-old biofilms, whereby
>86% of the bacteria were killed. DJK-5 was also able to kill >79% and >85% of bacteria,
respectively, after one-time and three brief treatments of 3-day-old biofilms. The combina-
tion of DJK-5 and chlorhexidine showed the best bacterial killing among all treatments, with
~83% and >88% of bacterial cells killed after 1 and 3 minutes, respectively. No significant
difference was found in the percentage of biofilm killing amongst three donor plaque sam-
ples after DJK-5 treatment. In particular, DJK-5 showed strong performance in inhibiting bio-
film development and eradicating pre-formed oral biofilms compared to L-enantiomeric
peptide 1018. DJK-5 was very effective against oral biofilms when used alone or combined
with chlorhexidine, and may be a promising agent for use in oral anti-biofilm strategies in the
future.
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Introduction
Despite the best efforts of dental health professionals, oral infections are still widespread.
Nearly 85% of North American adults between the ages of 20 and 64 have dental restorations,
and 23.7% of them have untreated dental caries [1]. More than 47% of American adults have
mild, moderate, or severe periodontitis [2]. Recent molecular methods have revealed that
almost all dental diseases are caused by dental biofilms that consist of multispecies microbial
communities [3–6]. Oral microbial biofilms are three-dimensionally structured communities
embedded in an exopolysaccharide matrix [7–10] attached to solid surfaces such as tooth
enamel, the surface of the root or dental implants [11], and they are extremely difficult to treat
[10]. The most notable difference between oral bacteria in dental biofilms and the same strain
grown planktonically is the increased tolerance/adaptive resistance of mature biofilm bacteria
to antimicrobial agents. According to Sedlacek and Walker [12], the concentration of the anti-
biotic required to inhibit the growth of bacterial strains in biofilms is approximately 250 times
greater than when the same strains are grown planktonically.
Cationic host defense peptides and their synthetic derivatives (innate defense regulators)
have been proposed to be alternative approach in the treatment of infections [13]. There are
more than 2,100 host defense peptides (also termed antimicrobial peptides) in nature and
these collectively have very broad activities including partially independent immunomodula-
tory, direct antimicrobial, and anti-biofilm activities [14–16]. However, one major obstacle
to their success as therapeutics in clinical trials is their inherent susceptibility to proteolytic
degradation [17–19]. Researchers have attempted to solve some of these limitations by physi-
cochemical modifications to the peptides. A potentially effective way to improve the proteo-
lytic stability of peptides is to incorporate non-natural D-isomers of amino acids, which
change the stereochemistry of the peptides making them more resistant to proteases. The
peptide with D-isomers can maintain the antimicrobial activity of the native sequence
because these peptides interact directly with, and often translocate across, the bacterial mem-
brane rather than requiring a specific receptor [20–22]. Recently, a broad-spectrum L-
amino-acid-containing peptide (1018) was shown to act against biofilm microbes by trigger-
ing the degradation of guanosine tetraphosphate (ppGpp) [23], which is important in biofilm
development of many bacterial species [24]. Peptide 1018 was also shown to inhibit oral pla-
que biofilm formation and to have antimicrobial activity against oral plaque biofilms [25].
DJK-5, a D-enantiomeric protease-resistant 12-amino-acid peptide, was also shown to have
broad-spectrum anti-biofilm activity through a similar mechanism to 1018
(promoting ppGpp degradation) [24, 26]. To date, there have been no studies on DJK-5 to
assess whether the peptide might be suitable for use in dental settings. Therefore, the objec-
tive of this project was to examine the effectiveness of the new antimicrobial peptide, DJK-5,
against oral plaque biofilms from different sources. Furthermore, it was also studied in com-
bination with another cationic agent, chlorhexidine (CHX).
Materials and Methods
Peptide Synthesis
Peptides 1018 and DJK-5 were synthesized by CPC Scientific (Sunnyvale, CA, USA) using
solid-phase 9-fluorenylmethoxy carbonyl (Fmoc) chemistry and purified to a purity of>95%
using reverse-phase high-performance liquid chromatography as previously described [22].
For the experiments the peptide was taken from peptide stocks in deionized water. The sterility
of the peptide stocks was checked.
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Plaque Bacteria Isolation and Measurement of Minimal Inhibitory
Concentration
The study was approved by the University of British Columbia Clinical Research Ethics Board
(certificate H12-02430). Written informed consent was obtained from the participants for col-
lecting the saliva and plaque bacteria in this study [25]. Plaque samples were collected with
sterile wooden toothpicks from three volunteers and grown overnight in the specified medium
[i.e., brain heart infusion (BHI) or Luria-Bertani (LB) broth] [25]. Bacteria were grown under
anaerobic conditions at 37˚C using anaerobic bags. The OD values of the plaque samples col-
lected at the beginning of bacterial culture for minimal inhibitory concentration assays were
0.10 for BHI medium and 0.05 for LB medium. Overnight cultures were diluted 1:100 in their
growth medium and transferred to 96-well plates containing increasing concentrations (0, 5,
10, 20, 40, and 80 μg/mL) of peptide DJK-5 in a biological safety cabinet (VWR Inc., Edmon-
ton, Alberta, Canada) at room temperature. After 24 hours of peptide treatment under anaero-
bic condition at 37˚C, bacterial growth was measured at an absorbance of 630 nm.
Biofilm Model
Biofilms were grown on sterile hydroxyapatite (HA) disks (Clarkson Chromatography Prod-
ucts, Williamsport, PA, USA) as previously described [25]. A saliva-coated HA disk (sHA) was
prepared by incubating each HA disk in the wells with saliva that was collected from three vol-
unteers. Supra- and subgingival plaque was collected from each of three healthy adult volun-
teers. Only one donor’s plaque bacteria were tested for inhibition by peptide 1018, while all 3
were used for DJK5. The sHA disks were incubated under anaerobic conditions at 37˚C for 3
days [25].
Biofilm Inhibition Test
Peptide 1018 or DJK-5 at two different concentrations (10 and 5 μg/mL, corresponding to 6.5
and 3.25 μM, respectively) was added to the plaque suspension at the beginning of biofilm
development, and grown anaerobically at 37˚C for up to 3 days [25]. For the control group,
sterile water was added into the culture medium instead of peptide. Three sHA disks were
included in each group at each time interval.
Long-term Anti-biofilm Effect of Peptides on Pre-formed Biofilms
Using the method described in the biofilm inhibition test, 9 biofilm-covered sHA disks
(3-day-old biofilm) per group were exposed to the peptide at the two different concentrations
(10 and 5 μg/mL) in BHI. Three sHA disks for each peptide concentration were incubated
with the peptide for 24 hours under anaerobic conditions at 37˚C (24-hour treatment) [25].
Another three sHA disks were similarly incubated for another 24 hours with the same concen-
tration of the peptide solution (48-hour treatment), and the remaining three disks in each
group were treated a third time and incubated for a third 24-hour period (72-hour treatment).
Control specimens with no peptide (only BHI + sterile water) were included for each time
period (24, 48, and 72 hours).
Short-term Anti-biofilm Effect of Peptides on Pre-formed Biofilms
Short term exposure to the peptides was performed as previously described [25]. Briefly, twelve
3-day-old plaque biofilm sHA disks were rinsed in phosphate buffered saline (PBS) at pH 7.0
for 1 minute. Disks were then immersed in 1 mL of 10 μg/mL (6.5 μM) of peptide 1018 or
DJK-5 for 1 or 3 minutes for either one or three treatments. Six disks treated with sterile water
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were used as the negative control group. Disks treated three times with the peptide were
immersed in PBS for 1 minute between each treatment.
Anti-biofilm Effect of Peptides in Combination with CHX
Three-day-old plaque biofilm disks were prepared and rinsed in PBS for 1 minute. The disks
were then divided into six treatment groups: (i) sterile water, (ii) 2% CHX, (iii) 10 μg/mL
(6.5 μM) of DJK-5, (iv) 10 μg/mL (6.5 μM) of 1018, (v) 2% CHX+ 10 μg/mL (6.5 μM) of DJK-
5, and (vi) 2% CHX+ 10 μg/mL (6.5 μM) of 1018. The sHA disks were immersed in 2-mL solu-
tions of each medicament for 1 or 3 minutes.
Confocal Laser Scanning Microscopic Examination of Biofilm Samples
Untreated or Treated with Peptides and/or CHX
The biofilms exposed to the different treatments were examined by viability staining and con-
focal laser scanning microscopy as previously described [25]. Biofilm disks were rinsed in
0.85% physiological saline for 1 minute before staining. LIVE/DEAD Bac-Light Bacterial Via-
bility kit L-7012 for microscopy and quantitative assays (Molecular Probes, Eugene, OR,
USA), containing two component dyes (SYTO 9 and propidium iodide in a 1:1 mixture) in
solution, was used for staining the biofilm following the manufacturer’s instructions. The exci-
tation/emission wavelengths were 480/500 nm for SYTO 9 and 490/635 nm for propidium
iodide for collecting the fluorescence. Fluorescence from each stained cell was viewed using a
confocal laser scanning microscope (FV10i-LIV, Olympus, Canada) equipped with 4 laser
diodes (405nm, 473nm, 559nm, 635nm) at a 1024 × 1024 pixel scan area using a 10 × lens.
Four random areas of the biofilm on each disk were scanned. A stack of 80–100 slices in
0.5 μm step sizes was captured from the top to the bottom of the biofilm. Confocal images
were then quantitated and analyzed (live/dead ratios) using Imaris 7.2 software (Bitplane Inc.,
St. Paul, MN, USA). The thresholds were set manually by adjusting the gain sensitivity of the
red and green fluorescence respectively to a level just below overexposure of areas in the phase
contrast mode. The thresholds were set by adjusting the gain sensitivity of the red and green
fluorescence respectively to a level where overexposure spots just disappeared in the phase
contrast mode. The absolute threshold value was the same for all the four scans for each sample
but might be different for different samples in order to avoid over- and underexposure of fluo-
rescence. The original confocal data was uploaded to Imaris 7.2 software and the intensity of
green and red fluorescence in full thickness of biofilm layers were captured automatically. The
software reconstructed the 2-dimentional intensity of fluorescence in all the layers to a
3-dimentional volume stack. The volumes for each fluorescence were then calculated and the
proportion of dead bacteria was calculated as follows: Dead bacteria% = (red fluorescence vol-
ume) / (green fluorescence + red fluorescence volume) × 100% [8,25].
Effect of Peptide DJK-5 on the Growth of Bacteria Suspended from
Biofilms into BHI or LB Broth Culture
Enterococcus faecalis VP3-181, Streptococcus mutans NCTC 10449, and three plaque samples
collected from three healthy volunteers were used for the broth culture experiment. The sHA
disks were placed into the 24-well plates, each containing 1.8 mL of BHI or LB. Each well was
inoculated with 0.2 mL of dispersed bacterial suspension (E. faecalis, S. mutans, and plaque)
[25]. Biofilm growth, preparation of bacterial suspensions and killing experiments were as pre-
viously described [25]. Briefly, after three days of incubation anaerobically (plaque and S.
mutans) or aerobically (E. faecalis) the biofilms were scraped off into BHI or LB medium and
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dispersed by pipetting and vortexing. The suspensions were adjusted to an OD405 of 0.25 for
the three microbe groups and a 100-μL sample of the bacteria in suspension was added to
400 μL of 8 μg/mL (5.2 μM) peptide DJK-5 in BHI or LB for 0, 30, 60, or 120 minutes. BHI or
LB alone was used as the negative control for each time interval. After each exposure, 100 μL
of bacterial solution was added to 900 μL of corresponding culture medium, serially diluted
and spotted onto blood agar plates for counting the colony forming units (CFU). The plates
were incubated anaerobically (S. mutans and plaque) or aerobically (E. faecalis), at 37˚C for 72
hours and the Log10CFU count was calculated. Three independent experiments were per-
formed with three replicates each [25].
Statistical Analysis
Statistical analysis was performed with SPSS 16.0 software for Windows (SPSS, Chicago, IL,
USA). Homogeneity of variance was determined using Levene’s test. Univariate ANOVA was
applied and post hoc multiple comparisons were used to isolate and compare the results
(mean ± standard deviation) at the P< 0.05 significance level.
Results
Peptide DJK-5 treatment did not substantially affect the planktonic growth of plaque bacterial
communities (Fig 1). When grown in BHI, DJK-5 only modestly reduced growth for the three
individual samples tested. Similar results were obtained when plaque bacteria were grown
planktonically in LB medium in the presence of the peptide, although the peptide was able to
significantly inhibit the growth of plaque from donor 2 (P = 0.001) at 40 μg/mL (26 μM) by
about 50%.
For studying the ability of DJK5 to inhibit biofilm bacteria, 1018 was used as a positive con-
trol [25]. As described below, in all instances DJK5 was superior to 1018 in its killing efficacy,
which might have been due to its resistance to the proteolytic activity of plaque biofilm bacte-
ria. In the biofilm growth inhibition test, significantly more microorganisms were killed at the
higher concentration (10 μg/mL, 6.5 μM) of DJK-5 than at the lower concentration (5 μg/mL,
3.25 μM) (Fig 2; P = 0.004) as shown previously for the positive control peptide 1018 [25] (Fig
2). Notably, DJK-5 showed much stronger effects than 1018 in killing significantly more bio-
film microbes at both concentrations (P< 0.01). There was no significant difference in the
proportion of killed bacteria between 1-, 2-, and 3-day-old biofilms by each of the peptides and
the proportion of bacteria killed by DJK-5 at 10 μg/mL (6.5 μM) at days 1 and 3 exceeded 85%
(Fig 2C). It is important to note that DJK-5 showed a similar killing pattern for the plaque bio-
films derived from the three different donors with virtually no killed bacteria in the negative
controls (water-treated; P = 0.004). Exposure to high concentrations of peptide DJK-5 during
biofilm growth reduced the plaque biofilm biovolume by more than 10-fold after 72 hours of
treatment (P = 0.000), resulting in only 8%, 8%, and 6% after 24-, 48-, and 72-hour time inter-
vals, respectively, compared to control biofilm (Fig 2D).
Exposure of pre-formed biofilms to DJK5 after 3 days of biofilm growth showed similar
results as obtained when the biofilms were exposed to the peptides from the beginning of
growth (Fig 3). Again, DJK-5 was considerably more effective in killing biofilm microbes than
the positive control peptide 1018 at both concentrations (Fig 3; P = 0.001). The number of
killed biofilm bacteria was significantly correlated with the concentration of peptide used
(P< 0.05). The proportion of dead bacterial cells at the higher DJK-5 concentration
(10 μg/mL, 6.5 μM) was similar between 1 day (85–91%) and 3 days (87–91%) in all three
donors’ biofilms and in all cases (Fig 3C).
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In short exposures of pre-formed biofilms, the proportion of dead bacterial cells was signifi-
cantly correlated with the agent of exposure and the number of repeated medicament applica-
tions (Fig 4). Peptide DJK-5 at 10 μg/mL (6.5 μM) applied for 3 minutes on 3-day-old biofilms
once or 3 times killed a much higher percentage of plaque biofilm bacteria (77–86%) than did
the positive control peptide 1018 (26–40%; P = 0.000). Again, no significant difference was
found in the sensitivity of biofilms from the three donors to peptide DJK-5.
The combination of DJK-5 and CHX showed the best results in bacterial killing among all
groups. The combination killed 83–87% and 88–90% of the bacteria after just 1 and 3 minutes,
respectively (Fig 5; P = 0.000). DJK-5 alone killed a much higher percentage of bacteria than
the combination of 1018 and CHX, or either CHX or peptide 1018 alone (P< 0.01).
Fig 1. Modest effect after 24 hours of increasing concentrations of peptide DJK-5 on the planktonic growth of plaque bacteria
grown in BHI or LB medium. Bacteria from plaque samples were grown in BHI and LB medium using 96-well polypropylene plates in the
presence of increasing concentrations of peptide DJK-5 and planktonic growth (measured absorbance at 630 nm) was assessed after 24
hours. Error bars represent the standard deviations calculated from three independent experiments.
doi:10.1371/journal.pone.0166997.g001
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The effect of peptide DJK-5 on bacteria suspended from 3-day-old biofilms into liquid cul-
ture in BHI or LB was examined over a period of 120 minutes (Fig 6). Peptide DJK-5 at 10 μg/
mL (6.5 μM) effectively prevented the growth of microbes resuspended from biofilms into both
culture media in a time-dependent manner. In addition to the prevention of growth, peptide
DJK-5 completely killed S. mutans and E. faecalis after 30 minutes of incubation in both culture
media. DJK-5 also led to very effective killing of microbes from the plaque biofilm with between
99 and 100% of the microbes being dead after 30 minutes. Plaque bacteria in LB medium were
modestly more susceptible to the action of the peptide killing than in BHI medium, which
might have been due to the increased nutrient content of BHI [27] that suppressed the forma-
tion of ppGpp, the target of DJK5. However, there is no statistically significant difference in
CFU numbers at different time intervals between LB and BHI (P = 0.085) (Fig 6).
Discussion
Bacterial resistance strategies to antimicrobial peptides that include the enzymatic degradation
of L-enantiomeric peptides have been described previously [28,29], and host proteases can also
Fig 2. Peptide DJK-5 had a greater effect than 1018 on oral multispecies biofilm development. (A, B) Confocal microscopy images of plaque
biofilm development on hydroxyapatite-coated disks over 3 days in the presence of (A) 5 μg/mL and (B) 10 μg/mL peptide or water as a control. The
scale bar represents 200 μm. (C) The proportion of dead biofilm bacterial cell volume during 3-day biofilm development in the presence of peptides
1018 and DJK-5. (D) Total biovolume of plaque biofilm formed in 3 days in the presence of peptides. Error bars represent the standard deviations
calculated from three independent experiments.
doi:10.1371/journal.pone.0166997.g002
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degrade such peptides during therapy. D-enantiomeric and retroinverso 12-mer peptides
based on the physicochemical properties of active anti-biofilm peptides were recently designed
[24,26]. As we have previously described, only 9 of the 20 natural amino acids (V, R, L, I, A,
W, F, K, Q) are included in the new designs 4 charged residues (most commonly R), 7 or 8
hydrophobic residues, and no more than 1 glutamine (Q). D-amino acids are not naturally
present in human peptides and therefore make them resistant to degradation by host proteases
[30]. This is especially important in the oral cavity where most organisms produce secreted
proteases [31]. Both the D-amino acid peptide DJK-5 and the L-amino acid peptide 1018
promote ppGpp degradation; in addition, the D-amino acid peptides have enhanced biological
activities in vitro [23,24]. DJK-5 was one of several recently designed peptides [30] which
Fig 3. Killing of microbes in 3-day-old biofilms exposed to the peptides for 24, 48, and 72 hours. (A, B) Confocal microscopy
images of 3-day-old plaque biofilms treated with (A) 5 μg/mL or (B) 10 μg/mL of peptides 1018 and DJK-5. Left column in (A) and (B):
samples treated once were challenged with peptide for 24 hours after biofilm formation for 3 days. Middle column in (A) and (B): biofilms
treated twice were exposed to peptide after day 3 for one more day (48 hours). Right column in (A) and (B): biofilms treated three times
were exposed to the peptide for two more days (72 hours). The scale bar in (A) and (B) represents 200 μm. (C) The proportion of dead
biofilm bacterial cell volume after exposure to the peptides for 24, 48, and 72 hours. Error bars represent the standard deviations
calculated from three independent experiments.
doi:10.1371/journal.pone.0166997.g003
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Fig 4. Effect of brief exposure to anti-biofilm peptides on pre-formed plaque biofilms: superior
efficacy of DJK-5. (A) CLSM images of 3-day-old plaque biofilms after one or three 3-minute exposures to
the peptides (10 μg/mL). The scale bar represents 200 μm. (B) The proportion of dead bacterial cells after
different peptide treatments for 3 minutes. Error bars represent the standard deviations calculated from three
independent experiments.
doi:10.1371/journal.pone.0166997.g004
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Fig 5. Superior killing of plaque biofilm microbes by peptide DJK-5 (cf. 1018) with chlorhexidine when used in
combination for 1 or 3 minutes. (A-C) 3D CLSM images; the scale bar represents 200 μm. (D) The proportion of dead microbial
cells after treatment with peptide, CHX, or the combination of both agents. Data calculated from A-C. Error bars represent the
standard deviations calculated from three independent experiments.
doi:10.1371/journal.pone.0166997.g005
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Fig 6. Growth curves of dental plaque, S. mutans, and E. faecalis suspended from sHA biofilms into BHI
or LB broth containing 400 μL of 8 μg/mL DJK-5 peptide. The concentrations of viable bacteria were
measured by performing CFU counts over time after resuspension of the biofilms. Error bars represent the
standard deviations calculated from three independent experiments.
doi:10.1371/journal.pone.0166997.g006
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PLOS ONE | DOI:10.1371/journal.pone.0166997 November 23, 2016 11 / 16
showed enhanced, broad-spectrum anti-biofilm activity when tested on several species of
Gram-negative pathogens [24,26]. According to de la Fuente-Nu´ñez [24], D-enantiomeric
peptides are designed not to be recognized by bacterial or host proteases that abound during
infections. They showed additive or synergistic effects with conventional antibiotics, rendering
biofilms more susceptible to these agents [24]. Human oral biofilms exist as multispecies com-
munities, which can be isolated and reconstructed in vitro in saliva-based model biofilms [32].
Plaque biofilms are known to contain both Gram-negative and Gram-positive species [33]. In
the present study, DJK-5 showed excellent performance in inhibiting oral biofilm growth and
in eradicating pre-formed oral biofilms, being considerably more potent than peptide 1018. In
the current study, DJK-5 displayed strong anti-biofilm activity and was able to kill most oral
bacteria in a short time of only 1 or 3 minutes.
Dental caries is a chronic disease of microbiological origin, and S. mutans has been impli-
cated as one of the major etiological pathogens responsible for the majority of caries [34,35]. E.
faecalis has gained attention in the endodontic literature because it can frequently be isolated
from root canals in cases of failed root canal treatment [36,37]. S. mutans and E. faecalis are
both facultative anaerobes. In order to have equally long time of growth, S. mutans was cul-
tured anaerobically and E. faecalis was grown in the air. Our CFU determinations on biofilm
bacteria showed that DJK-5 had strong antimicrobial ability in single-species and oral multi-
species biofilms. Data from 16S rRNA gene cloning and sequencing studies indicate that the
oral cavity has roughly 700 microbial phylotypes, of which slightly less than half have been cul-
tivated [38].
Viability staining, which might better reflect the true viability of oral biofilm bacteria than
culturing during some growth phases [39], further confirmed the effectiveness of DJK-5 both
with regard to reduction in biofilm biovolume and in direct killing of the bacteria. Viability
staining is based on the principle that the red stain (propidium iodide) enters only those cells
where the cell membrane is damaged, whereas the green stain (SYTO 9) can enter all cells. It is
therefore possible that in some cases red fluorescence may give a false-positive result when inter-
preted as a killed cell, although the cell is still alive although damaged. Despite its shortcomings,
viability staining has become the method of choice in measuring biofilm killing [8,25,39]. The
methodology allows for the measurement of the relative proportion of damaged/killed bacteria
in each biofilm specimen, which is not possible by using traditional culture methods [39].
With the complexity of multispecies microbial communities, it is difficult to determine the
functions of individual species contributing to the observed physiological changes. Biofilms
are structured microbial communities embedded in extracellular polymeric substances, and
engaged in a distinct lifestyle accompanied by specific gene expression profiles. The extracellu-
lar polymeric substance matrix provides several functional purposes for the biofilm, such as
protecting bacteria from environmental stresses and providing mechanical stability [40,41].
The multispecies biofilms on sHA grown from plaque from three different donors showed no
differences in their susceptibility to either DJK-5 or the combination of DJK-5 and 2% CHX.
This result might indicate that the source and possible differences in the species composition
of these multispecies biofilms had no major impact on their susceptibility to these agents,
which is in accordance with a previous study [42]. Previous studies [42,43] showed that mature
multispecies biofilms grown on sHA disks from different donors for 3 weeks were substantially
more resistant to disinfection than younger 1- and 2-week-old biofilms. Biofilms from six dif-
ferent sources showed a similar, time-dependent susceptibility pattern [43]. However, in our
studies, the specific bacterial species present in the different inocula from dental plaque sam-
ples and the residual bacteria after peptide treatment were not identified. Our future studies
will focus on identifying these species and exploring the metabolic diversity and peptide sus-
ceptibility of oral multispecies biofilms.
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Chlorhexidine is an active ingredient in many mouthwash products used to reduce dental
plaque and planktonic oral bacteria. The antimicrobial action of CHX is non-specific, and
while it effectively prevents plaque growth on a clean tooth surface, it is less effective against
established oral biofilms. In addition, CHX has a bitter taste and tendency for staining the
teeth [44,45]. Previous study [25] and current results have shown that peptide 1018 is compati-
ble with and can act in combination with CHX to attack established plaque biofilms. In the
present study, the combined use of DJK-5 and CHX showed a strong additive effect in bacte-
rial killing. Although DJK-5 alone worked quite well, the combination of DJK-5 and CHX had
the highest anti-biofilm effect in short-term exposures against oral multispecies biofilms, when
compared to DJK-5 alone or peptide 1018 with or without CHX. Based on these experiments,
we anticipate that DJK-5 could have potential for use in daily oral care and/or rapid disinfec-
tion during oral surgery.
In conclusion, peptide DJK-5 showed strong performance in inhibiting biofilm growth,
eradicated pre-formed oral biofilms, and showed efficient anti-biofilm activity in short-term
exposures of 1 and 3 minutes. DJK-5 was more effective against oral biofilms than peptide
1018 when used alone or together with CHX, and may be a promising agent for use in oral
anti-biofilm strategies in the future.
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